Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > 2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
EU-2022-annual-report-eudravigilance-european-parliament-council-commission_en_21Mar2023-1Download
Ryan McArthur 27 March 2023 All news
  • ← WHO Pharmaceuticals Newsletter
  • Pharmacovigilance – Questions and answers – Access to medicines not authorised in France for the treatment of serious diseases – ANSM →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • FAQ for the webinar on the new European legislation on clinical trials for medicinal products
  • EMA: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 12 May 2023
  • EMA – Annual Report 2022
Copyright © 2018 - Pharmya - Legal terms - Quality Policy